Clearance Isn’t Enough: Proving Cybersecurity in 2026 with Christian Espinosa

Why It Matters

Because clearance no longer guarantees market success, proven cyber‑security determines hospital adoption, investor confidence, and regulatory compliance, directly impacting revenue and valuation.

Key Takeaways

• FDA now demands cyber security built into device lifecycle.
• SBOM must be a living, operational inventory post‑launch.
• Coordinated vulnerability disclosure requires documented, traceable response processes.
• Hospitals and investors increasingly scrutinize operational security beyond clearance.
• State privacy laws force targeted go‑to‑market strategies for manufacturers.

Summary

2026 marks the moment regulatory frameworks finally caught up with cyber‑security realities for medical‑device manufacturers. The FDA’s updated FDI guidance and Quality System Regulation now require security to be designed into products and supported by an operational plan for post‑market incidents, while the EU’s AI Act and Cyber‑Resilience Act echo the same expectations for AI‑enabled devices.

Christian Espinosa explains that a software bill of materials (SBOM) is no longer a static spreadsheet for submission; it must be a living inventory that drives patching decisions after launch. Coordinated vulnerability disclosure (CVD) processes are also under scrutiny, with auditors demanding proof of validation, traceability, and timely customer notifications rather than mere paperwork.

He cites a recent FDA audit where a client had to demonstrate actual adherence to its CVD procedures, and likens the SBOM to a Ford Pinto recall—highlighting the need for clear, actionable communication when a component is vulnerable. Hospitals now act as de‑facto regulators, demanding evidence of operational security, and investors treat cyber‑risk as a top‑line valuation factor.

The shift forces manufacturers to embed security into quality management systems, adopt state‑specific privacy compliance, and craft phased go‑to‑market strategies. Failure to do so can stall product clearance, erode hospital contracts, and jeopardize financing, making cyber‑security a decisive competitive advantage.

Original Description

Cybersecurity in medical devices is no longer just about passing regulations—it’s about proving real-world security.

In this episode, Christian Espinosa (Blue Goat Cyber) breaks down how the landscape has shifted in 2026. From FDA expectations to hospital scrutiny and investor pressure, manufacturers are now required to go beyond checklists and demonstrate operational cybersecurity across the entire product lifecycle.

We cover:

Why clearance is no longer the finish line

The evolution of the Software Bill of Materials (SBOM) into a living, operational tool

How hospitals are becoming stricter than regulators

Why cybersecurity is now a top reason for rejected submissions

What investors are really looking at when evaluating risk

If you're building, investing in, or regulating medical technology, this conversation will change how you think about cybersecurity.

🔔 Subscribe for more insights on medtech, cybersecurity, and compliance

📩 Connect with us for more conversations like this

00:00 Introduction: Cybersecurity Reality in 2026

00:14 What Changed: New FDA Pressure & Enforcement

00:34 Guest Intro: Christian Espinosa (Blue Goat Cyber)

00:57 Cybersecurity Is No Longer a Checklist

01:24 Proving Security: Evidence & Accountability

01:58 SBOM Explained: From Spreadsheet to Living Inventory

02:30 Post-Market Responsibility & Risk Management

03:16 Coordinated Vulnerability Disclosure (CVD) Explained

03:47 From Paperwork to Real Processes

04:36 FDA Audits: Proof, Traceability & Evidence

05:31 EU Regulations & AI Cybersecurity Requirements

05:35 Cybersecurity = Product Quality

06:30 Hospitals as New Gatekeepers

07:03 “Clearance Gets You to the Door”

07:40 What Hospitals Expect from Manufacturers

08:32 Proof Over Promises

08:51 Investor Perspective: Cybersecurity as Risk

09:20 Why Devices Get Rejected Today

09:59 Cybersecurity & ROI for Investors

10:23 Navigating Global & US State Regulations

11:04 Go-To-Market Strategy vs Compliance Risk

11:58 Scaling from Easier Markets First

12:09 Closing Remarks